UA107691C2 - Противораковая комбинация лекарственного средства на основе артемизинина с другими химиотерапевтическими средствами - Google Patents
Противораковая комбинация лекарственного средства на основе артемизинина с другими химиотерапевтическими средствамиInfo
- Publication number
- UA107691C2 UA107691C2 UAA201208932A UAA201208932A UA107691C2 UA 107691 C2 UA107691 C2 UA 107691C2 UA A201208932 A UAA201208932 A UA A201208932A UA A201208932 A UAA201208932 A UA A201208932A UA 107691 C2 UA107691 C2 UA 107691C2
- Authority
- UA
- Ukraine
- Prior art keywords
- artemisinin
- chemotherapeutic agents
- product based
- medicinal product
- cancer combination
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 2
- 239000012635 anticancer drug combination Substances 0.000 title 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 title 1
- 229960004191 artemisinin Drugs 0.000 title 1
- 229930101531 artemisinin Natural products 0.000 title 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 abstract 1
- BJDCWCLMFKKGEE-KDTBHNEXSA-N Dihydroartemisinin (DHA) Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](O)[C@@H]4C BJDCWCLMFKKGEE-KDTBHNEXSA-N 0.000 abstract 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 abstract 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 1
- 229940127093 camptothecin Drugs 0.000 abstract 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000138 intercalating agent Substances 0.000 abstract 1
- 229960004768 irinotecan Drugs 0.000 abstract 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 abstract 1
- 229950011068 niraparib Drugs 0.000 abstract 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 abstract 1
- 229960000572 olaparib Drugs 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 abstract 1
- 229950011257 veliparib Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09180666 | 2009-12-23 | ||
| PCT/EP2010/068924 WO2011076547A1 (en) | 2009-12-23 | 2010-12-06 | Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA107691C2 true UA107691C2 (ru) | 2015-02-10 |
Family
ID=41647059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201208932A UA107691C2 (ru) | 2009-12-23 | 2010-12-06 | Противораковая комбинация лекарственного средства на основе артемизинина с другими химиотерапевтическими средствами |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9023861B2 (enExample) |
| EP (1) | EP2515898A1 (enExample) |
| JP (1) | JP2013515690A (enExample) |
| KR (1) | KR20120096053A (enExample) |
| CN (1) | CN102665711A (enExample) |
| AR (1) | AR079654A1 (enExample) |
| AU (1) | AU2010335422A1 (enExample) |
| BR (1) | BR112012015606A2 (enExample) |
| CA (1) | CA2780591A1 (enExample) |
| EA (1) | EA201200934A1 (enExample) |
| IL (1) | IL220561A0 (enExample) |
| IN (1) | IN2012DN03914A (enExample) |
| MX (1) | MX2012006738A (enExample) |
| MY (1) | MY157475A (enExample) |
| NZ (1) | NZ599878A (enExample) |
| PH (1) | PH12012500893A1 (enExample) |
| SG (1) | SG10201408485SA (enExample) |
| TW (1) | TWI482621B (enExample) |
| UA (1) | UA107691C2 (enExample) |
| WO (1) | WO2011076547A1 (enExample) |
| ZA (1) | ZA201205360B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9314473B2 (en) | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
| US9801851B2 (en) * | 2012-05-23 | 2017-10-31 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias |
| EP3137076A4 (en) * | 2014-05-02 | 2017-12-06 | Emory University | Selective chemotherapy treatments and diagnostic methods related thereto |
| US9918972B2 (en) * | 2014-12-23 | 2018-03-20 | The University Of Maryland, Baltimore | Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents |
| CN105963262B (zh) * | 2016-06-06 | 2018-11-30 | 北京林业大学 | 一种两亲性果胶-双氢青蒿素纳米粒子的制备方法 |
| CN110051850A (zh) * | 2016-08-26 | 2019-07-26 | 宁国市厚普生物科技有限公司 | 一种复合物在制备用于治疗黑色素瘤的药物中的应用 |
| CN109453156A (zh) * | 2018-11-22 | 2019-03-12 | 中国中医科学院中药研究所 | 一种抗肿瘤组合物及其应用、抗肿瘤药物 |
| EP3868372A1 (en) * | 2020-02-19 | 2021-08-25 | JLP Health GmbH | A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer |
| CN114053276B (zh) * | 2020-07-30 | 2024-05-07 | 江苏天士力帝益药业有限公司 | 一种parp抑制剂tsl-1502中间体tsl-1502m的用途 |
| CN114053271B (zh) * | 2020-07-30 | 2024-05-07 | 江苏天士力帝益药业有限公司 | 一种含有tsl-1502m的药物组合物及其应用 |
| CN114010643A (zh) * | 2021-11-23 | 2022-02-08 | 温州医科大学 | 双氢青蒿素在抗肿瘤药物的制备中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5578637A (en) | 1995-05-03 | 1996-11-26 | University Of Washington | Methods of inhibition or killing cancer cells using an endoperoxide |
| SI1044977T1 (en) | 1999-03-09 | 2002-08-31 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Camptothecin derivatives having antitumor activity |
| KR100390332B1 (ko) | 2000-08-02 | 2003-07-07 | 유원민 | 항말라리아제와 항암제의 병용투여에 의한 항암제 복합 조성물 |
| WO2004071506A1 (en) * | 2003-02-12 | 2004-08-26 | Georgetown University | Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections |
| EP1658844A1 (en) | 2004-10-19 | 2006-05-24 | Gerold Schuler | Use of artemisinin derivatives in the manufacture of a medicament for the treatment of melanoma |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| US8143284B2 (en) * | 2006-10-05 | 2012-03-27 | Abbott Laboratories | Poly(ADP-ribose)polymerase inhibitors |
| WO2008063644A1 (en) | 2006-11-20 | 2008-05-29 | Cephalon, Inc. | Method of radio-sensitizing tumors using a radio-sensitizing agent |
| CN101125140B (zh) * | 2007-09-18 | 2011-04-13 | 浙江大学 | 二氢青蒿素在制备增强化疗药物抗肿瘤疗效的药物中的应用 |
| WO2009114459A2 (en) * | 2008-03-10 | 2009-09-17 | The Trustees Of The University Of Pennsylvania | Anti-neoplastic combination therapeutic regimen involving co-disruption of parp pathway and mre11/rad50/nbs1 complex and compositons useful therein |
| CN101380325A (zh) * | 2008-10-23 | 2009-03-11 | 上海交通大学 | 青蒿素衍生物与长春瑞滨的组合物及其应用 |
| CN101428034B (zh) * | 2008-12-12 | 2012-02-08 | 广州市允中投资发展有限公司 | 具有增效减毒特点的抗肿瘤组合药物 |
| CN101856352A (zh) * | 2009-04-10 | 2010-10-13 | 中国科学院上海生命科学研究院 | 青蒿素及其衍生物对化疗剂的协同作用 |
-
2010
- 2010-11-22 TW TW099140203A patent/TWI482621B/zh not_active IP Right Cessation
- 2010-12-06 UA UAA201208932A patent/UA107691C2/ru unknown
- 2010-12-06 WO PCT/EP2010/068924 patent/WO2011076547A1/en not_active Ceased
- 2010-12-06 US US13/518,185 patent/US9023861B2/en not_active Expired - Fee Related
- 2010-12-06 JP JP2012545201A patent/JP2013515690A/ja not_active Ceased
- 2010-12-06 IN IN3914DEN2012 patent/IN2012DN03914A/en unknown
- 2010-12-06 MX MX2012006738A patent/MX2012006738A/es not_active Application Discontinuation
- 2010-12-06 CN CN2010800580524A patent/CN102665711A/zh active Pending
- 2010-12-06 NZ NZ599878A patent/NZ599878A/en not_active IP Right Cessation
- 2010-12-06 AU AU2010335422A patent/AU2010335422A1/en not_active Abandoned
- 2010-12-06 PH PH1/2012/500893A patent/PH12012500893A1/en unknown
- 2010-12-06 CA CA2780591A patent/CA2780591A1/en not_active Abandoned
- 2010-12-06 KR KR1020127016599A patent/KR20120096053A/ko not_active Withdrawn
- 2010-12-06 SG SG10201408485SA patent/SG10201408485SA/en unknown
- 2010-12-06 BR BR112012015606A patent/BR112012015606A2/pt not_active IP Right Cessation
- 2010-12-06 EP EP10788312A patent/EP2515898A1/en not_active Withdrawn
- 2010-12-06 EA EA201200934A patent/EA201200934A1/ru unknown
- 2010-12-06 MY MYPI2012001992A patent/MY157475A/en unknown
- 2010-12-21 AR ARP100104807A patent/AR079654A1/es unknown
-
2012
- 2012-06-21 IL IL220561A patent/IL220561A0/en unknown
- 2012-07-18 ZA ZA2012/05360A patent/ZA201205360B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12012500893A1 (en) | 2012-11-12 |
| US9023861B2 (en) | 2015-05-05 |
| KR20120096053A (ko) | 2012-08-29 |
| MY157475A (en) | 2016-06-15 |
| EA201200934A1 (ru) | 2012-12-28 |
| BR112012015606A2 (pt) | 2018-05-29 |
| MX2012006738A (es) | 2012-07-03 |
| SG10201408485SA (en) | 2015-01-29 |
| ZA201205360B (en) | 2013-05-29 |
| CA2780591A1 (en) | 2011-06-30 |
| EP2515898A1 (en) | 2012-10-31 |
| IN2012DN03914A (enExample) | 2015-09-04 |
| AR079654A1 (es) | 2012-02-08 |
| US20120258181A1 (en) | 2012-10-11 |
| JP2013515690A (ja) | 2013-05-09 |
| CN102665711A (zh) | 2012-09-12 |
| IL220561A0 (en) | 2012-08-30 |
| AU2010335422A1 (en) | 2012-06-07 |
| TWI482621B (zh) | 2015-05-01 |
| TW201138764A (en) | 2011-11-16 |
| WO2011076547A1 (en) | 2011-06-30 |
| NZ599878A (en) | 2014-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA107691C2 (ru) | Противораковая комбинация лекарственного средства на основе артемизинина с другими химиотерапевтическими средствами | |
| GT200800145A (es) | Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceutica y un conjunto (kit) de dicha formulacion | |
| EA201390783A1 (ru) | Биоразлагаемые композиции для доставки лекарственных средств | |
| CY1119140T1 (el) | Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους | |
| WO2016161342A3 (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| EP2004172A4 (en) | ACTIVE INK PROCESSING, STRUCTURES AND COMPOSITIONS FOR NASOLACRIMAL SYSTEM | |
| EP2462246A4 (en) | QUICK INITIATION AND / OR TERMINATION OF THE ADMINISTRATION OF SUBSTANTIALLY STABILIZED MEDICINAL PRODUCTS | |
| HRP20160551T1 (hr) | Kombinirana terapija s pripravcima nanočestica taksana i hedgehog inhibitora | |
| EP2279008A4 (en) | PHARMACEUTICAL COMPOSITIONS OF PACLITAXEL, PACLITAXEL ANALOGUE OR PACLITAXEL CONJUGATES AND RELEVANT MANUFACTURING AND USE METHOD | |
| EA201200937A1 (ru) | Твердая лекарственная форма тикагрелора | |
| CU20080052A7 (es) | Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo | |
| WO2007069272A3 (en) | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer | |
| GT201400059A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos | |
| EA200870421A1 (ru) | Димеры производных артемизинина, их получение и их применение в терапии | |
| CR20120068A (es) | Formulaciones de imiquimod de concentración de dosificación inferior y regímenes de dosificación cortos para tratar verrugas genitales y perianales | |
| BR112013033544A2 (pt) | dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos | |
| MX2015003343A (es) | Tratamiento combinado con el farmaco de interferencia de netrina-1 y el farmaco quimioterapeutico. | |
| ATE523200T1 (de) | Kombination mit sapacitibin (2'-cyano-2'-desoxy- n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosin) und einem zytotoxischen mittel | |
| TR200903036A2 (tr) | Tiyokolşikozit ve non-steroidal anti-enflamatuar ilaç kombinasyonları | |
| FR2903404B1 (fr) | Nouveaux derives tetracycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| MX2016007741A (es) | Preparacion de combinacion farmaceutica que comprende un inhibidor de hmg-coa reductasa y un inhibidor de la absorcion de colesterol. | |
| WO2011058508A3 (en) | Compositions for the treatment of chemoresistant leukaemia and/or of potentially chemoresistant leukaemia | |
| BRPI0714672B8 (pt) | derivados de camptotecina, composição farmacêutica contendo os mesmos e seu uso | |
| PH12014501601A1 (en) | Artemisinin-based combination therapy for treating viral mediated disease | |
| WO2016175551A3 (ko) | 항체에 덴드론이 접합된 면역접합체 및 이의 용도 |